Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2012

View Archived Issues

New Pfizer product shows promising anticancer actvity

Genentech presents PK/PD model for IBD therapy

Companies seek approval in Japan for biosimilar of filgrastim

New promising results disclosed on brodalumab in plaque psoriasis

New technology launched by arGEN-X

Xention discloses encouraging phase I data on candidate AF drug

Shire exercises option to license candidate agent for CNS disorders

Scientists identify new potential biomarker of myxoid/round cell liposarcoma

Halo Therapeutics reports on independent review of lead product

PROLOR Biotech launches pediatric trial of long-acting human growth hormone

Proteonomix announces completion of private placement

Patrys reports on phase I PAT-SM6 trial

Taisho reports novel sodium/glucose cotransporter 1 inhibitors

New candidate pain therapies designed at Gruenenthal

Novel inhibitors of MPGES-1 developed

Cedars-Sinai Medical Center presents new potential atherosclerosis therapies

Karo Bio scientists discover new ER-beta ligands

Aerpio discloses phase I data on agent for diabetic macular edema

EMA accepts lomitapide MAA for review

First patient enrolled in phase I/II study of PET imaging agent for brain cancer

Milestone reached in OncoTherapy Science/Shionogi collaboration

Taiho and Nordic Group launch Teysuno

Telotristat etiprate receives FDA orphan drug status

FDA's ODAC votes regarding approval of ridaforolimus

GSK gives update on FDA's ODAC review of Votrient

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...